Printer Friendly

Articles from M2 Pharma (May 8, 2020)

1-18 out of 18 article(s)
Title Author Type Words
Alpha Software Releases First Multi-Language COVID-19 Risk Assessment App. 239
Aptar Submits Application for Emergency Use Authorization to the German Regulatory Agency BfArM for ActivShield FFP2 Decontamination System. 320
Bioclinica reports availability of comprehensive COVID-19 clinical endpoint adjudication solution. 186
Bridge Biotherapeutics receives South Korean approval for BBT-176. 243
Cell and Gene Therapies a USD 3.8bn Market Despite COVID-19 Crisis, Report Says. Report 375
Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker. 257
FDA Permits Use of Aidoc's AI Algorithms to Detect and Prioritize Incidental CT Findings Associated With COVID-19. 326
Genelux Corporation provides update of Type C Meeting with FDA for the treatment of ovarian cancer. 214
OPTI Medical Systems wins US FDA's EUA for OPTI SARS-CoV-2 RNA PCR Test Kit for detection of SARS-CoV-2. 199
Premier Predictive Technology Identifies Surges in COVID-19 Cases and Supply Needs. 390
Prescryptive Health collaborates with Bartell Drugs for COVID-19 antibody testing. 186
Prescryptive partners with Bartell Drugs to expand access to reliable, safe and secure COVID-19 testing. 197
Protagonist Therapeutics reveals initial data from study of PTG-300 in patients with polycythemia vera. 210
SE Texas ER and Hospital Among First of Texas Facilities to Receive FDA Authorized Cellex Antibody Test for COVID-19. 256
Soligenix announces USD840,000 from non-dilutive funding under New Jersey Technology Business Tax Certificate Transfer Programme. 204
Vault Health Delivers Access to the First FDA EUA Approved At-Home Saliva Test for COVID-19. 248
Viracor Eurofins reports availability of highly accurate antibody tests for SARS-CoV-2. 192
ZYUS Collaborates with USask's VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19. 277

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |